RAPT Therapeutics (RAPT) Wells Fargo 20th Annual Healthcare Conference 2025 summary

Strategic focus and lead asset overview

• Focused on developing transformative therapies for high-value immunology and inflammation diseases, targeting large markets with unmet needs.

• RPT-904, a next-generation long-acting anti-IgE antibody, was in-licensed and is positioned for food allergy and chronic spontaneous urticaria (CSU).

• Food allergy and CSU represent $40B and $5B U.S. markets, respectively, with significant growth potential.

• RPT-904 is in phase 2 development, sharing the same epitope and mechanism as omalizumab, supporting high technical success probability.

• The asset aims to disrupt the standard of care by improving efficacy, safety, and patient access.

Market landscape and differentiation

• Omalizumab (Xolair) is the current standard, but has limitations: lower affinity, shorter half-life, and excludes high-IgE/high-weight patients.

• RPT-904 introduces mutations for improved half-life and affinity, enabling Q8 or Q12 week dosing versus Q2/Q4 week for omalizumab.

• Enhanced dosing flexibility and access to previously ineligible patients are key differentiators.

• Market research shows strong preference among patients, prescribers, and payers for less frequent, potentially at-home dosing.

• Compliance and economic benefits are expected from reduced ER visits and improved patient experience.

Competitive dynamics and biosimilars

• Omalizumab's patent expires this year; biosimilars expected late next year, with anticipated 30-40% price erosion.

• RPT-904's pricing strategy will benchmark against branded omalizumab, aiming for premium positioning due to differentiation.

• Product profile targets omalizumab-like efficacy and safety with less frequent dosing as the minimum bar for payer coverage.